Erratum to: “Establishing New Acceptance Limits for Dissolution Performance Verification of USPC Apparatus 1 and 2 Using USPC Prednisone Tablets Reference Standard”

Anthony J. DeStefano • Walter W. Hauck • Erika S. Stippler • William E. Brown • Chensheng Li • Gloria G. Huang • Barbara J. Jones • Kevin O'Hool • William F. Koch • Roger L. Williams

Published online: 1 February 2011
© Springer Science+Business Media, LLC 2011

Erratum to: Pharm Res
DOI 10.1007/s11095-010-0295-3

We regret that the original article duplicated Figure 5a and omitted Figure 5b. The figures and caption should have been published as shown here.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s11095-010-0295-3>.

A. J. DeStefano (✉) • W. W. Hauck • E. S. Stippler • W. E. Brown • C. Li • B. J. Jones • K. O'Hool • W. F. Koch • R. L. Williams
US Pharmacopeial Convention
Rockville, Maryland 20852, USA
e-mail: ajd@usp.org

Present Address:
G. G. Huang
US Food and Drug Administration
Silver Spring, Maryland, USA

Fig. 5 GM and %CV by Laboratory, Apparatus 2. Error bars are 95% confidence intervals based on each laboratory's between-position variability. Horizontal lines are the combined value from the collaborative study and the single-stage Lot PI PVT limits for an instrument with six positions. Limits for seven- and eight-position instruments are tighter. The limits for the geometric mean are those at the time of the collaborative study